Valuing a pharmaceutical plant in Morocco — where the building stops and the process begins

A pharmaceutical site — a manufacturing plant, a contract-manufacturing unit, a research and development centre — is among the most specialised property assets in existence. Cleanrooms, qualified utilities, regulated flows of people and materials, compliance with good manufacturing practice. Almost no comparable transactions, a building fabric that cannot be separated from the process it houses, and licences without which nothing runs at all. This guide sets out the method as a RICS valuer applies it in Morocco: depreciated replacement cost under VPGA 5 for the fabric and the integrated installations, an explicit split between property, process and licences, an alternative use test, and the recurring traps.

A strategic industry housed in unusual property

Morocco's pharmaceutical industry occupies an established place in the national industrial fabric: local manufacture of medicines, contract manufacturing for international principals, and distribution. The corresponding sites — concentrated in particular in the industrial zones of the Casablanca axis and its region — combine production buildings, quality control laboratories, temperature-controlled storage areas and heavy utilities: air handling, purified water production, clean steam and process fluids.

For a valuer, these sites concentrate everything that makes an asset “specialised” in Red Book terms: the near-total absence of a transactional market, the interlocking of fabric and process, and dependence on regulatory authorisation. Direct comparison simply does not work. The method organises itself instead around cost, around the lease where one exists, and around what the site would be worth to somebody who wanted the building but not the pharmacy. That triangulation is the same discipline we apply to any specialised industrial asset in Morocco: never a single method, always a bundle of approaches with assumptions stated on the face of the report.

What actually makes the asset

Before any figure can be produced, the valuer has to understand what is physically in front of them, because on this asset class the ordinary vocabulary of industrial property is not sufficient.

• Cleanrooms. Controlled-atmosphere zones with dedicated partitions and filtered ceilings, pressure cascades and decontaminable finishes. They are physically integrated into the building, yet they hold value only for a qualified process.
• Qualified utilities. Air handling units, purified water generation, compressed air, clean steam: heavy installations whose worth depends on their documentary qualification as much as on their physical condition.
• Regulated flows. Segregation of personnel, materials and waste, airlocks, dedicated storage zones. The floor plan is itself a regulatory object, difficult to alter without requalification.
• Compliance. Establishment licences, compliance with good manufacturing practice, inspections. Without them the site does not manufacture. These are intangible assets distinct from the bricks and mortar and, in most instructions, outside the property valuation altogether.
• Temperature-controlled storage. Cold rooms and climate-controlled areas which bring parts of the site close to the logic of cold-store logistics, where insulation, plant and continuity of the cold chain drive both cost and depreciation.

Read against the ordinary yardsticks of Moroccan industrial property — clear heights, floor loadings, dock arrangements, yard depth, the sort of criteria set out in our note on the technical characteristics of industrial buildings — a pharmaceutical plant looks like an ordinary shed carrying a very expensive, very perishable second building inside it.

The RICS method: depreciated replacement cost as the spine

Scoping first: draw the boundary before you draw a figure

The VPS 3 scoping stage is decisive here. The terms of engagement must fix the dividing line between property and process: shell, envelope and general fit-out on one side; cleanroom installations and qualified utilities on another; production equipment last, either reported separately or excluded. Without that split written down at the outset, two honest valuers can produce two figures that cannot be compared with each other — and a lender or auditor cannot tell which one answers their question.

DRC under VPGA 5 for the specialised property component

Depreciated replacement cost takes the cost of rebuilding the shell, the pharmaceutical fit-out and the integrated utilities as new, and deducts physical, functional and economic depreciation. The mechanics are those set out in our DRC and DCF methodology guide, but with a markedly heavier documentary requirement: qualification files, maintenance history, records of modifications. Functional obsolescence bites harder here than on almost any other industrial asset, because standards move and processes change while the fit-out stays where it was built.

The income approach where the site is let

Where the property is held in a propco and let to an operating company, a sustainable market rent is capitalised. The scrutiny that applies to intra-group leases applies here in full — a rent set for tax or treasury reasons is not evidence of market rent — exactly as it does when the walls and the business are separated in a healthcare setting. The parallel with a private clinic valuationis close: the same question of what the property alone would command, stripped of the operator's own covenant.

The alternative use test

An industrialist from another sector will strip out the cleanrooms. On conversion, the value falls back to that of an ordinary industrial building — shell, clear heights, floor slabs, land — less the cost of decommissioning and removal. This is the highest and best use discipline applied honestly, and the gap between value in operation and value on conversion belongs on the face of the report, not in a footnote. It is frequently the single most useful number a buyer's board will read.

The inputs to collect

• Land and planning. The titre foncier — Morocco's registered land title, which confers indefeasible ownership once registered — industrial zoning, the compliance status of what has been built, and any easements.
• Technical. Detailed drawings, a breakdown of floor areas by zone (production, quality control, storage, utilities, offices), a description of the cleanrooms and utilities, ages and maintenance history.
• Regulatory. Establishment licences, available certificates and inspection reports, the status of qualifications. The valuer works from the documents supplied and does not stand in the place of the health authorities.
• Contractual. Leases or occupation agreements where the property and the operation are held separately, and any structuring contract-manufacturing agreements that bear on the durability of the site.
• Accounting. Carrying values on the balance sheet, particularly where the instruction feeds fair value accounts under IFRS 13 or an impairment test.

A comparable exercise on a smaller life sciences asset — where the same walls-versus-plant question arises at a domestic scale — is set out in our medical analysis laboratory case study, and a regulated food production site is taken through the same cost-and-income discipline in our Sidi Bernoussi food processing plant case study.

Five traps that distort the figure

• Mistaking historic cost for value. Heavy investment in cleanrooms does not translate mechanically into market value. Functional obsolescence arrives quickly when standards evolve and processes change.
• Skipping the property/process boundary. Without a split agreed at scoping, the report mixes assets of different natures and becomes unusable for the bank and for the auditor alike.
• Treating compliance as given. Value in operation presupposes the continuity of licences. Any uncertainty must be converted into an explicit assumption, not passed over in silence.
• Overstating conversion value. Stripping out pharmaceutical fit-out costs money. The alternative value is that of an industrial shell, not of an equipped plant.
• Neglecting economic depreciation. A site oversized relative to its order book suffers an economic obsolescence that DRC must capture, over and above physical wear.

One further point that owners often discover late: reinstatement cost for insurance purposes is a different exercise from market value, answering a different question with a different figure, as explained in our note on reinstatement value for industrial and logistics buildings. On a pharmaceutical site, where the fit-out can dwarf the shell, the divergence between the two is at its widest.

What the report is used for

Pharmaceutical instructions serve precise needs: the sale or acquisition of a site, often inside a wider industrial transaction; bank financing secured on the property; a contribution in kind or a group restructuring; consolidated accounts at fair value; and insurance at reinstatement cost. Prepared by RICS-certified valuers and compliant with RICS Red Book Global Standards, the report supplies a documented value with traceable assumptions — suitable for amicable negotiation and adversarial discussion, which is the only currency that counts in front of an auditor or a lender. It is a private valuation; where a matter reaches litigation, the court appoints its own expert.

Fees start from MAD 3,500 net of tax for standard assets; a pharmaceutical site is quoted individually according to size, technical complexity and purpose, with a quotation within 24 hours and a report in five to eight working days, or 48 to 72 hours on an expedited basis. ReaConsult: founded in 2019, over 5,000 valuations delivered across six Moroccan cities, more than a thousand a year, 4.9/5 from 47 Google reviews. Our broader offer for industrial owners is set out on our industrial real estate valuation page, and briefs can be sent through our contact page.

Frequently asked questions

Note. This article sets out a valuation methodology compliant with RICS standards (Red Book, VPS 3 and VPGA 5 DRC). It does not replace an instruction on a specific file. Pharmaceutical licensing and compliance are matters for the competent authorities — confirm your position with them and with your own advisers.